Core Viewpoint - Morgan Stanley has downgraded the sales guidance for Giant Bio (02367) for 2025 from a growth of 25% to flat or slight decline [1] Group 1: Revenue Forecasts - Morgan Stanley has reduced revenue forecasts for Giant Bio for 2025, 2026, and 2027 by 20%, 32%, and 35% respectively [1] - The net profit for 2025 and 2026 is expected to decline by 8% year-on-year, with a rebound of 20% anticipated in 2027 [1] Group 2: Market Conditions - The company initially expected a sales growth of 20% to 30% during Q4 and the Double Eleven shopping festival, but failed to meet these targets due to industry headwinds [1] - Intense price competition for similar products and declining returns on investment from live-streaming sales have led the company to prioritize price stability and profitability, resulting in a sales decline and weakened operating leverage [1] Group 3: Future Strategies - Morgan Stanley anticipates that the company will take various actions to drive sales recovery, including increasing marketing investments to counteract previous controversies and rebuild brand momentum [1] - The company is expected to reduce reliance on live-streaming sales and promotional events like Double Eleven and 618 [1] - A new beauty injection product is set to launch in 2026, which is expected to have a limited initial contribution but confirms that the company's past R&D efforts are still in the early stages of commercialization [1]

Core Viewpoint - Morgan Stanley has downgraded the sales guidance for Giant Bio (02367) for 2025 from a growth of 25% to flat or slight decline, reflecting challenges in the industry [1] Group 1: Revenue Forecasts - Morgan Stanley has reduced revenue forecasts for Giant Bio for 2025, 2026, and 2027 by 20%, 32%, and 35% respectively [1] - The firm anticipates a year-on-year net profit decline of 8% for 2025 and 2026, with a rebound of 20% expected in 2027 [1] Group 2: Market Challenges - The company initially expected a sales growth of 20% to 30% in Q4 and during the Double 11 shopping festival, but failed to meet these targets due to industry headwinds [1] - Intense price competition for similar products and declining returns on investment from live-streaming sales have led the company to prioritize price stability and profitability, resulting in a sales decline and weakened operating leverage [1] Group 3: Future Strategies - Morgan Stanley expects the company to take various actions to drive sales recovery, including increasing marketing investments to counteract previous controversies and rebuild brand momentum [1] - The company is expected to reduce reliance on live-streaming sales and promotional events like Double 11 and 618 [1] - A new injectable beauty product is set to launch in 2026, with initial contributions expected to be modest, indicating that the company's past R&D efforts are still in the early stages of commercialization [1]

Summary of Giant Biogene Holding Co Ltd (2367.HK) Conference Call Company Overview - **Company**: Giant Biogene Holding Co Ltd (2367.HK) - **Industry**: Consumer Health, specifically in the biotechnology sector focusing on recombinant collagen products - **Market Cap**: Approximately US$4.47 billion - **Current Stock Price**: HK$34.72 - **Price Target**: HK$42.00, down from HK$78.00 Key Points Financial Performance and Challenges - **Sales Growth**: The company revised its sales growth forecast from approximately 25% to a flat or mild decline for 2025 due to negative publicity and operational imbalances [2][11] - **Sales Decline**: Expected sales decline of 22% year-over-year in the second half of 2025, with specific brands like Comfy and Collgene facing declines of 26% and 11% respectively [11][12] - **Marketing Strategy**: Increased marketing spend is planned to restore brand momentum, with a shift in focus from influencer-driven sales to broader marketing efforts [3][20] Operational Adjustments - **R&D Strength**: The company has a robust R&D pipeline that supports new product launches, including an aesthetic injectable expected in 2026 [3][20] - **Cost Management**: The company is prioritizing pricing stability and profitability, which has led to a decline in sales but aims to improve operational efficiency [2][3] - **Marketing Spend**: The online advertising and promotion (A&P) ratio is expected to increase from approximately 45% to 55% in 2026-27, focusing on social media and branding campaigns [3] Earnings and Valuation - **Earnings Estimates**: Significant cuts to earnings estimates were made, with a new price target based on a 22x P/E for 2026, down from 30x for 2025 [4][19] - **Profit Margins**: Gross profit margins are projected to decline from 80.9% in 2025 to 79.0% in 2026, reflecting pricing adjustments and increased operational expenses [16][18] - **Net Profit Forecast**: Expected net profit decline of 8% annually for 2025 and 2026, with a potential recovery of 20% in 2027 [17][18] Market Dynamics - **Competitive Landscape**: Increased competition from new entrants and established brands in the recombinant collagen market is anticipated, which may pressure pricing and marketing strategies [12][26] - **Consumer Acceptance**: The success of new products and marketing campaigns is critical; failure could lead to weaker sales and diminished brand equity [24][25] Risks and Catalysts - **Key Risks**: Uncertainty in new product performance, effectiveness of marketing campaigns, and potential pricing adjustments pose risks to revenue growth [24][25][26] - **Potential Catalysts**: Increased marketing intensity, new product launches, and share buybacks are seen as potential drivers for recovery [4][20] Investment Thesis - **Overweight Rating**: Despite current challenges, the company is viewed as having strong R&D capabilities and a rich product pipeline, which could lead to a turnaround [20][33] - **Bull and Bear Cases**: In a bull-case scenario, the stock could reach HK$66.00, while in a bear-case scenario, it could drop to HK$26.00 [21][22] Conclusion Giant Biogene is navigating significant challenges due to external pressures and operational imbalances. However, with a focus on marketing, R&D, and new product launches, the company aims to stabilize and eventually grow its sales and profitability. The investment outlook remains cautiously optimistic, supported by the potential for recovery in the coming years.

巨子生物回购明细 证券时报·数据宝统计，巨子生物在港交所公告显示，12月16日以每股34.680港元至35.400港元的价格回 购40.00万股，回购金额达1402.61万港元。该股当日收盘价34.720港元，上涨0.52%，全天成交额2.78亿 港元。 自12月9日以来公司已连续6日进行回购，合计回购240.00万股，累计回购金额8462.61万港元。 其间该 股累计下跌4.62%。（数据宝） | 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2025.12.16 | 40.00 | 35.400 | 34.680 | 1402.61 | | 2025.12.15 | 40.00 | 35.240 | 34.440 | 1391.73 | | 2025.12.12 | 40.00 | 35.220 | 35.000 | 1403.64 | | 2025.12.11 | 40.00 | 35.360 | 34.200 | 1388.76 | | 2025.12.10 | 40.00 | ...

格隆汇12月16日丨巨子生物(02367.HK)公告，12月16日耗资1402.6万港元回购40万股。 ...

巨子生物(02367)发布公告，该公司于2025年12月16日斥资1402.61万港元回购40万股股份，每股回购价 格为34.68-35.4港元。 ...

智通财经APP讯，巨子生物(02367)发布公告，该公司于2025年12月16日斥资1402.61万港元回购40万股 股份，每股回购价格为34.68-35.4港元。 ...

| 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02367 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年12月15日 | 1,070,904,000 | | 0 | | 1,070,904,000 | | 1). 其他 (請註明) | | | % | | | | | 見B部分 | | | | | | | | 變動日期 | 2025年12月16日 | | | | | | | 於下列日期結束時的結存 (註5及6) | 2025年12 ...

Core Insights - The article discusses the stock buyback activities of various companies, highlighting the total amounts and quantities repurchased, with Tencent Holdings leading the buyback efforts [1][2]. Group 1: Buyback Overview - Tencent Holdings (00700) repurchased 1.051 million shares for a total of 636 million, representing 0.995% of its total share capital [2]. - Xiaomi Group (01810) repurchased 7.2 million shares for 302 million, accounting for 0.430% of its total share capital [2]. - China COSCO Shipping Holdings (01919) repurchased 2.95 million shares for 40.016 million, which is 3.089% of its total share capital [2]. Group 2: Notable Buybacks - Kuaishou Technology (01024) repurchased 462,000 shares for 29.9304 million, representing 0.191% of its total share capital [2]. - Kingsoft Corporation (03888) repurchased 702,800 shares for 19.9994 million, which is 0.580% of its total share capital [2]. - Country Garden Services (06098) repurchased 3 million shares for 18.9615 million, accounting for 1.284% of its total share capital [2]. Group 3: Other Companies - Coolpad Group (02369) repurchased 3.16 million shares for 4.1717 million, representing 7.986% of its total share capital [2]. - China Petroleum & Chemical Corporation (00386) repurchased 764,000 shares for 3.306 million, which is 0.190% of its total share capital [2]. - Mengniu Dairy (02319) repurchased 200,000 shares for 2.9675 million, accounting for 0.762% of its total share capital [2].

格隆汇12月15日丨巨子生物(02367.HK)公告，12月15日耗资1391.7万港元回购40万股。 ...